Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment.
| dc.contributor.author | Oliveira, Lenice Kappes Becker | |
| dc.contributor.author | Totou, Nádia Lúcia | |
| dc.contributor.author | Moura, Samara Silva de | |
| dc.contributor.author | Kangussu, Lucas Miranda | |
| dc.contributor.author | Sinisterra Millán, Ruben Dario | |
| dc.contributor.author | Santos, Maria Jose Campagnole dos | |
| dc.contributor.author | Coelho, Daniel Barbosa | |
| dc.contributor.author | Santos, Daisy Motta | |
| dc.contributor.author | Santos, Robson Augusto Souza dos | |
| dc.date.accessioned | 2019-04-25T13:51:58Z | |
| dc.date.available | 2019-04-25T13:51:58Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The aim of this study was to determine whether a oral formulation of angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported less pain immediately (3.46± 0.64 vs. placebo 3.80± 0.77 cm) and 24h after exercise (3.07±0.71 vs. 3.73±0.58cm placebo) and higher MS at 24h (24±12N) and 48h (30±15N) vs. placebo (-8 ± 9 N and -10 ± 9 N). The CK for Ang-(1-7) (0.5 ± 0.1 and 0.9±0.2 U/L) were lower at 48 and 72h vs. placebo (fold changes of 1.7±0.5 and 1.5±0.3 U/L). The TNF-α level was lower in the treated group post-exercise (38 ± 2.5 pg/ml) vs. placebo (45 ± 2.9 pg/ml) but no significant changes were observed for IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7) may attenuate pain, some of the muscle damage markers and improves performance following eccentric exercise. | pt_BR |
| dc.identifier.citation | OLIVEIRA, L. K. B. et al. Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment. International Journal of Sports Medicine, v. 39, n. 10, p. 743-748, 2018. Disponível em: <https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0633-8892>. Acesso em: 20 fev. 2019. | pt_BR |
| dc.identifier.issn | 0172-4622 | |
| dc.identifier.uri | http://www.repositorio.ufop.br/handle/123456789/11126 | |
| dc.identifier.uri2 | https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0633-8892 | pt_BR |
| dc.language.iso | en_US | pt_BR |
| dc.rights | restrito | pt_BR |
| dc.subject | Physical performance | pt_BR |
| dc.subject | Muscular damage | pt_BR |
| dc.title | Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment. | pt_BR |
| dc.type | Artigo publicado em periodico | pt_BR |